You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.
During Q2, three American MSOs are projected to have generated quarterly revenue in excess of $100 million, with Curaleaf and Trulieve expected to surpass Green Thumb Industries, the first company to have achieved that milestone during Q1. Trulieve derives almost all of its revenue from Florida, while Curaleaf and GTI are more diversified. Neither company breaks out revenue by market, but Illinois and Pennsylvania appear to be driving GTI’s growth, with a substantial contribution from Nevada as well. Curaleaf’s composition is shifting after its recent acquisition of Select, which added substantial exposure in California and other Western states. It cites its current top 5 states as Massachusetts, Florida, Arizona, New Jersey and Nevada.
While these three MSOs are the largest, their total share of the U.S. market is not dominant. Even with Curaleaf’s pending Grassroots acquisition, which will expand its leadership position, the $1 billion in revenue that analysts currently project for 2021 would be less than 5% of the overall legal market. It’s important to understand that there isn’t just one market in the U.S. Instead, there are many different markets, with some states permitting adult-use while others limit cannabis to medical. Each state offers different dynamics. For instance, New York, currently a medical-only market, has 10 licenses. On the other hand, Oklahoma, also a medical-only market, has open licensing and currently thousands of licenses. We have profiled several state markets this year.
American cannabis operators will struggle to achieve market dominance in any given state. An outlier, of course, is Trulieve in Florida. Based on production assets, Cresco Labs and GTI are likely to have very high share in Illinois. Many states with limited licenses control the market to the extent it would prevent dominant market share. New York restricts its 10 medical cannabis providers to just four dispensaries each. Pennsylvania is a rapidly growing market that also caps the number of dispensaries any provider may operate. At the same time, states that have relatively open licensing can be so competitive that it will be difficult to have high share within the market. A good example of this is Oregon.
Looking ahead, leading MSOs are likely to expand their share of the market. Those that are best capitalized and can generate positive cash flow fall into this camp. Many companies that aren’t as well capitalized or with cost structures that remain too high will cede some market share. Recent announcements by Acreage Holdings, Harvest Health & Recreation and MedMen reinforce this point. Readers can stay on top of this trend by monitoring the Public Cannabis Company Revenue & Income Tracker, which breaks out profitability and revenue levels.
Several companies have been able to access substantial debt over the past year or so, including Columbia Care, Cresco Labs, Curaleaf, GTI, Harvest Health and Trulieve. Some have also been able to obtain substantial capital from sale-leasebacks, particularly through Innovative Industrial Properties, which speaks regularly of its core tenants and its desire to expand its relationship with them. The REIT just raised another $259 million dollars. IIP’s public company tenants include Cresco Labs (5 properties), GTI (3 properties), MJardin (1 property), Trulieve (2 properties) and Vireo Health (4 properties).
While the retrenchment of several public companies that expanded too rapidly will likely reward those that have grown more prudently, we note that there are several private MSOs that will benefit as well. We think a great place to start one’s search for these companies is IIP’s tenant list, which includes private operators Ascend Wellness, Emerald Growth Partners, Grassroots (pending acquisition by Curaleaf), Green Leaf, Green Peak Innovations, Holistic, King’s Garden, LivWell, Maitri Genetics, Parallel, PharmaCann, The Green Solution Colorado (pending acquisition by Columbia Care), The Pharm and Vertical. Note that we have interviewed several of these companies.
While we don’t expect the total U.S. market to be dominated by a few companies, we do anticipate that several leading MSOs will become quite substantial in size over the next few years as they gain share in a rapidly growing market. Most of the growth is likely to be organic, but we anticipate tuck-in acquisitions as well as expansion into new markets, particularly California, where most of the larger MSOs have not yet moved aggressively.
Cresco Labs, with its headquarters in Chicago, is one of the largest vertically-integrated multi-state cannabis operators in the United States. With experienced management, access to capital and a demonstrated growth strategy, the company has been busy with its integration of Origin House, allowing the company to leverage California to grow its Brand further. Concurrently, Cresco Labs has been benefiting from very positive sales growth trends in Illinois, Pennsylvania and Ohio. The company’s strategic footprint includes 6 of the 10 largest U.S. states.
Get up to speed by visiting the Cresco Labs Investor Dashboard that we maintain on their behalf as a client of New Cannabis Ventures. Click the blue Follow Company button in order to stay up to date with their progress.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Exclusive: American Cannabis Operator Stocks Gain 29% in Q2
- Ancillary Cannabis Supplier GrowGeneration Prices $42 Million Equity Offering at $5.60 Per Share
- Exclusive: Canadian Cannabis Producer Stocks Pull Back 11% in June
- Cannabis REIT Raises Another $225 Million
- Cresco Labs Expands Innovative Industrial Properties Partnership with $28.8 Million Massachusetts Cannabis Sale-Leaseback
- Curaleaf Holdings to Raise C$27.5 Million in Private Placement Sale of Shares at C$7.70
- Exclusive: Global Cannabis Stocks Post First Winning Quarter Since Early 2019
- Exclusive: How Cannabis Testing Company SC Labs Builds Collaborative Relationships with Clients
- MedMen Substantially Dilutes Shareholders Again to Appease Creditors
- Exclusive: New Cannabis Ventures Upgrades Canadian Cannabis Index Criteria
- Exclusive: Profitable Privately Owned Cannabis Operator Verano Expects Strong Organic Growth
- Exclusive: Public Cannabis Companies Continue to Rapidly Ramp Up Revenue
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.
View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than US$7.5M per quarter.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Alan & Joel